Blocking TNF-α causes a decline in IL-1 and IL-6, as well as adhesion molecules and vascular endothelial growth factors (VEGFs), and in disorders such as autoimmune diseases, TNF blockers are being suggested to be used in hospitalized patients with severe inflammatory response [159]. Here, TNF is linked to autoimmune disease.